article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

While global M&A deal value across sectors remained relatively flat overall , pharmaceuticals and life sciences M&A in 2024 dipped relative to the prior year. Indeed, the largest US biotech exit in 2024 was Vertex Pharmaceuticals $4.9 Immunology deals stood out, including Vertex Pharmaceuticals $4.9 from 2023. [1]

M&A 64
article thumbnail

Securities Litigation Against Life Sciences Companies 2024 Year in Review

JD Supra: Mergers

Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies. By: Goodwin

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

Global Newswire by Notified: M&A

Palvella Therapeutics to debut on Nasdaq under the ticker symbol PVLA as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases

article thumbnail

Josh Mastracci joins TM Capital as Director

TM Capital

Josh has extensive experience completing transactions across key healthcare services sectors including physician practice management, ambulatory surgery centers, and pharmaceutical services.

Capital 52
article thumbnail

Cooley’s M&A Insights for Q3 2022

Cooley M&A

Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals. Notable public deals. Lavoro to Become Publicly Traded Through Business Combination With TPB Acquisition Corporation I. TCGplayer Agrees to Sell to eBay. DigitalOcean Agrees to Buy Cloudways. Sixth Street Invests in Blueprint Medicines.

M&A 69
article thumbnail

Cooley’s 2019 Life Sciences M&A Year in Review

Cooley M&A

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 2019 was a banner year for billion-dollar life sciences M&A transactions.

M&A 40
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40